New systemic drugs in the treatment of gastrointestinal cancer

Current Opinion in Oncology

Volumn 8, Issue 4, 1996, Pages 317-320

  Ogawa, Makoto ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; PACLITAXEL; RALTITREXED;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH CANCER; TREATMENT OUTCOME;

EID: 0029784255     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199607000-00009     Document Type: Review

References (21)

1. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mukai M: Antitumor activity of 7-ethyl-10-[4-(l-pipreridino)-1-piperidino]carbonyloxy-camptothecin, a novel watersoluble derivative of camptothecin, against murine tumors. Cancer Res 1987, 47:5944-5947.
2. Ogawa M, Ariyoshi Y: New anticancer drugs under clinical trials in Japan. Hemat Oncol Clin North Am 1994, 8:277-287.
3. Sakata Y, Nakao I, Futatsuki K, Kambe M, Wakui A, Taguchi T: An early phase II trial of CPT-11 in patients with advanced gastrointestinal cancer. Jpn J Soc Cancer Ther 1992, 27:2028-2035.
4. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994, 21:1033-1038.
5. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe K, Taguchi T, Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993, 11:909-913.
6. Conti JA, Kemeny N, Saltz L, Tong W, Chon TC, Pulliam M: Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer [abstract]. Proc ASCO 1994, 13:195.
7. Pitot HC, Wenda D, O'Connell MJ, Wieand HS, Mailliard JA: A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc ASCO 1994, 13:197.
8. Rothenberg ML, Eckardt JR, Buris HA III, Nelson J, Kuhn JG, Chen SF, Hilsenbeck SG, Chark GM, Field SM, Rodnquez GI, et al.: Irinotecan (CPT-11) as second line therapy for patients with 5-FU-refractory colorectal cancer. Proc ASCO 1994, 13:198.
9. Bugat R, Rougier E, Sue PH, Becouan Y, Natieff I, Ychon M, Culine S, Extra JM, Adenis A, Ganem G, Giovannini M, et al.: CPT-11 (Irinotecan) as second line therapy in advanced colorectal cancer (CRC): preliminary results of a multicenter phase II study. Proc ASCO 1994, 13:200.
10. Sakata Y, Shimada Y, Yoshino M, Kambe M, Futatsuki K, Nakao I, Ogawa N, Wakui A, Taguchi T: A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. Jpn J Cancer Chemother 1994, 21:1039-1046.
11. Wagener DJTH, Verdonk HER, Dirix LX, Catimel G, Siegenthafer P, Buitenhuis M, Mathien-Bone, Verweij J: Phase II trial of CPT-11 in patients with advanced pancreatic cancer: an EORTC Early Clinical Trials Group study. Ann Oncol 1995, 6:129-132.
12. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: a novel investigational antimicrotubule agent J Natl Cancer Inst 1990, 82:1247-1259.
13. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994, 86:1086-1091.
14. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 1995, 13:2643-2655.
15. Taguchi T, Furue H, Niitani H, Ishitsni K, Kanamaru R, Hasegawa K, Ariyoshi Y, Noda K, Furuse K, Furuoka M, Yakushiji M, Kashimura M: Phase I clinical trial of RP56976 (doxetaxel): a new anticancer drug. Jpn J Cancer Chemother 1994, 21:1997-2005.
16. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kayl S, Wanders J, Franklin H, Lebail N, Verweij J, for the EORTC Early Clinical Trials Group: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994, 70:380-383.
17. Taguchi T: An early phase II clinical study of RP56976 (doxetaxel) in patients with cancer of the gastrointestinal tract Jpn J Cancer Chemother 1994, 21:2431-2437.
18. Rougier PH, Forni MDe, Adenis A, Ducrenx M, Djazoule K, Adamus D, Bounterre J, Clouet P, Blanc C, Bayssas M, Armand JP: Phase II study of taxotere (RP56976, docetaxel) in pancreatic adenocarcinoma (PAC) [abstract]. Proc ASCO 1994, 13:200.
19. Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harap KR, Stephens TC, Azab M, Boyle FT: ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 1995, 31A:1277-1282.
20. Adenis A, Cunningham D, Van Cutsem E, Zalberg J, Francois E, Shomagel JH, Green M, Starkhammer H, Perrz-Manha G, Seymour L: Tomudex (ZD1694), a new active agent in the treatment of advanced colorectal cancer [abstract]. Ann Oncol 1994, 5(suppl 8):189.
21. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svesson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymour L, Lowery K: Tomudex (ZD1694): results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leukopenia. Eur J Cancer 1995, 31A:1945-1954.